Evidence map›Paper›PMID 23265147›Full record

ReviewExpert review of gastroenterology & hepatology2013

Helicobacter pylori infection in Japan.

Seiji Shiota, Kazunari Murakawi, Rumiko Suzuki, Toshio Fujioka, Yoshio Yamaoka

Abstract readReview
In one paragraph

Review in Expert review of gastroenterology & hepatology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 46 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
46citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

46 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Trial
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Trends of EarlyJournal of clinical medicine · 2024
    Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Article
  15. CagA and VacA inhibit gastric mucosal epithelial cell autophagy and promote the progression of gastric precancerous lesions.Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences · 2022
    Article
  16. Risk factors for gastric cancer in Japan in the 2010s: a large, long-term observational study.Gastric cancer : official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association · 2022
    Observational
  17. Review
  18. Overview ofGut and liver · 2021
    Review
  19. Review
  20. Endoscopic and histological features ofJGH open : an open access journal of gastroenterology and hepatology · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Seiji ShiotaDepartment of Environmental and Preventive Medicine, Oita University Faculty of Medicine, 1-1 Idaigaoka, Hasama-machi, Yufu City, Oita 879-5593, Japan.
Kazunari Murakawi
Rumiko Suzuki
Toshio Fujioka
Yoshio Yamaoka

Funding

REGULATION OF CXC CHEMOKINE EXPRESSION BY H. PYLORIR01DK062813 · NIDDK · BAYLOR COLLEGE OF MEDICINE · PI YAMAOKA, YOSHIO · 2004 to 2013
$3.0M
NIDDK NIH HHS DK62813NIDDK NIH HHS R01 DK062813
6 · The paper itself

Abstract

The prevalence of Helicobacter pylori infection is gradually decreasing in Japan. On the main island of Japan, nearly all H. pylori isolates possess cagA and vacA with strong virulence. However, less virulent H. pylori strains are frequently found in Okinawa where cases of gastric cancer are the lowest in Japan. Eradication therapy for peptic ulcer, idiopathic thrombocytopenic purpura, gastric mucosa-associated lymphoid tissue lymphoma and early gastric cancer after endoscopic resection has been approved by the Japanese national health insurance system. However, the Japanese Society for Helicobacter Research recently stated that all 'H. pylori infection' was considered as the indication for eradication irrespective of the background diseases. To eliminate H. pylori in Japan, the Japanese health insurance system should approve the eradication of all H. pylori infections.

Indexed as

Asian PeopleAnti-Bacterial AgentsDisease ProgressionDrug Therapy, CombinationHelicobacter InfectionsHelicobacter pyloriHumansJapanPrevalenceProton Pump InhibitorsRisk FactorsStomach NeoplasmsStomach UlcerTime FactorsTreatment OutcomeVirulenceAnti-Bacterial AgentsProton Pump Inhibitors

Identifiers

PMID23265147
PMCPMC3732492

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.